Figure 4.

Inhibition of Brk’s kinase function increases cell sensitivity to chemotherapeutic agents. Triple negative MDA-MB-231 and MDA-MB-436 cells were seeded and allowed to adhere overnight in 96 wells plates. They were then treated with the Brk inhibitor Compound 4f alone (A,D) or in combination with paclitaxel (B,E) or doxrubicin (C,F) over a range of concentrations (0–5 µm). In B–F, open squares represent cells treated with doxorubicin or paclitaxel only; closed diamonds represent cells treated with both 4f and the chemotherapeutic agent. Cell viability was determined by MTT assay and expressed as a percentage of the control (vehicle only) wells. The mean % survival (+/− SD) of n = 3 experiments is plotted; * indicates p < 0.05.